【Product for Licensing】DLL3 ADC!Two >1B licensing deals by Hengrui/IDEAYA Bio and Innovent Bio/Roche in just 4 days

If you are interested in similar assets, please contact DrugTimes BD Team at BD@drugtimes.cn asap. Many thanks!

In just 4 days, there have been two major licensing deals related to DLL3 ADC, with >1 billion US dollars for each deal.

  1. Hengrui Medicine and IDEAYA Biosciences Deal:
    • On December 29, 2024, Hengrui Medicine announced that it has granted exclusive rights to develop, manufacture, and commercialize the DLL3 ADC innovative drug SHR-4849 globally (excluding the Greater China region) to the U.S. company IDEAYA Biosciences.
    • According to the agreement, IDEAYA Biosciences will pay Hengrui Medicine an upfront fee of $75 million, development milestones totaling up to $200 million, and sales milestones totaling up to $770 million, with the potential total payment amount reaching $1.045 billion.
    • Hengrui Medicine will also receive sales royalties at a percentage in the one to two-digit range of actual annual net sales.
  2. Innovent Biologics and Roche Deal:
    • On January 2, 2025, Innovent Biologics has reached a global exclusive licensing agreement with Roche for the DLL3 ADC drug IBI3009.
    • Under the agreement, Innovent Biologics will receive an upfront payment of $80 million, potential development and commercialization milestones of up to $1 billion, and sales royalties at a mid-teen percentage.
    • IBI3009 has obtained clinical trial approval in Australia, China, and the United States, and completed the first patient dosing in Phase I clinical studies in December last year.
    • Innovent Biologics and Roche will jointly be responsible for the early development of the ADC candidate, with subsequent clinical development to be led by Roche.

If you are interested in similar assets, please contact DrugTimes BD Team at BD@drugtimes.cn asap. Many thanks!~

发布者:DrugTimes001,转载请首先联系contact@drugtimes.cn获得授权

(0)
打赏 为好文打赏 支持药时代 共创新未来! 为好文打赏 支持药时代 共创新未来!
上一篇 2025年1月2日 11:57
下一篇 2025年1月2日 15:21

相关推荐

公众号
公众号
分享本页
返回顶部